SOHO 2023 | Updates on the use of molecular monitoring to detect MRD in AML
Laura Dillon
• 8 Sep 2023
Laura Dillon, PhD, FACMG, National Institutes of Health, Bethesda, MD, talks on the use of molecular monitoring in acute myeloid leukemia (AML), commenting on efforts to translate next-generation sequencing (NGS) measurable residual disease (MRD) testing to the clinic. Dr Dillon also discusses aims to standardize MRD testing in this disease setting and highlights ongoing trials investigating MRD-directed interventions. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
